Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) saw a large decrease in short interest in the month of October. As of October 13th, there was short interest totalling 619,419 shares, a decrease of 58.0% from the September 29th total of 1,476,241 shares. Currently, 5.4% of the shares of the stock are short sold. Based on an average trading volume of 1,779,376 shares, the short-interest ratio is currently 0.3 days.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. lifted its holdings in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 105,409 shares of the biotechnology company’s stock after acquiring an additional 76,046 shares during the quarter. KCG Holdings Inc. owned 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent quarter. 2.25% of the stock is currently owned by institutional investors.

Ritter Pharmaceuticals (NASDAQ RTTR) opened at 0.365 on Friday. The company’s market cap is $5.39 million. The company has a 50-day moving average of $0.44 and a 200 day moving average of $0.44. Ritter Pharmaceuticals has a 52 week low of $0.32 and a 52 week high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). On average, equities analysts forecast that Ritter Pharmaceuticals will post ($0.42) EPS for the current fiscal year.

Several brokerages recently commented on RTTR. Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. HC Wainwright dropped their price objective on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating for the company in a research note on Monday, October 23rd. Chardan Capital dropped their price objective on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating for the company in a research note on Tuesday, August 8th. Maxim Group reissued a “hold” rating on shares of Ritter Pharmaceuticals in a research note on Wednesday, July 5th. Finally, Roth Capital set a $2.00 price objective on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Ritter Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $2.92.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/28/ritter-pharmaceuticals-inc-rttr-short-interest-down-58-0-in-october.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.